MRD-Guided Chemotherapy After Pancreatic Cancer Surgery
Part of Cancer clinical trials.
This trial tests whether using a special blood test (MRD) to guide chemotherapy after pancreatic cancer surgery can improve outcomes. It is for people who have had their cancer completely removed and are ready for standard follow-up therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You had surgery to remove pancreatic ductal adenocarcinoma (the most common type) and the cancer was stage I-III with clear margins (R0 resection).
- Your surgery was less than 12 weeks ago.
- You have fully recovered from surgery and can receive chemotherapy.
- You have enough tumor tissue from your surgery to be tested for MRD (minimal residual disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at using a special blood test (ctDNA MRD) to track how well the tumor responds to chemotherapy before surgery for pancreatic cancer. It may help doctors decide if the treatment is working and guide next steps.
This study uses a special blood test to look for tiny amounts of cancer DNA after your pancreatic cancer surgery. It may help doctors see early if the cancer is coming back, so they can act sooner.
This study checks if a simple blood test can find tiny bits of cancer DNA after your pancreatic surgery, which may help detect if cancer comes back earlier than scans. By joining, you'll help doctors learn how to better monitor the disease and guide future treatments.
This trial is for people who had surgery for pancreatic cancer and are now deciding on maintenance therapy. A special blood test (ctDNA) may help doctors choose the best follow-up treatment to prevent the cancer from coming back.
This study looks at whether a blood test for leftover cancer cells (called MRD) after stomach cancer surgery can help guide treatment. It is for people with a certain type of stomach cancer that has spread to nearby tissues but not to distant organs, and who are having surgery as their first treatment.
This trial studies a blood test that looks for tiny traces of cancer-related DNA (called ctDNA) in people with pancreatic cancer that can be removed with surgery. The goal is to see whether this test can better predict how the cancer behaves and guide treatment decisions around surgery.
Hear when a new Pancreatic Adenocarcinoma Resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.